SBIR Phase I: Development of reliable pyrazinamide susceptibility testing at neutral pH

这个小企业创新研究（SBIR）第一阶段项目的更广泛的影响/商业潜力旨在开发一种新的结核病（TB）检测方法。这项技术将导致比目前的护理标准更准确和可靠的结果。该项目将改善结核病治疗结果。此外，它还将通过提高治愈率和减少耐药性的传播，遏制耐多药结核病发病率的上升。 该小型企业创新研究（SBIR）第一阶段项目建议使用结核病药物敏感性测试的标准方案，在中性pH值下，在重组体内条件下测定PZA的敏感性。目前的PZA敏感性试验是不可靠的，因为它是在酸性pH条件下进行的。接种量不适当的M。结核病可能中和培养基的pH或由于在酸性pH条件下的生长抑制而不能生长。这导致经常出现错误的结果，导致治疗不当。拟议的研究将提出一种新的方法，在专有培养基中确定中性pH下的表型PZA易感性。本项目将优化PZA药敏试验的培养基，采用结核病药敏试验的标准方案进行药敏试验，具有可靠性和准确性。总之，这项研究不仅将建立一个可靠的PZA敏感性测试，而且还将联合收割机所有结核病药物敏感性结合在一个有效的系统中。该奖项反映了NSF的法定使命，并被认为值得通过使用基金会的知识价值和更广泛的影响审查标准进行评估来支持。

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project aims to develop a new test for tuberculosis (TB). This technology will lead to more accurate and reliable results than the current standard of care. This project will improve TB treatment outcomes. Furthermore, it will combat the increasing incidence of multidrug-resistant TB by increasing the cure rate and reducing the spread of drug resistance. This Small Business Innovation Research (SBIR) Phase I project proposes to determine PZA susceptibility at neutral pH in reconstituted in vivo condition using the standard protocol of TB drug susceptibility testing. The current PZA susceptibility test is unreliable because it is performed in an acidic pH condition. An inappropriate inoculum size of M. tuberculosis may neutralize the pH of the medium or fail to grow due to growth inhibition at the acidic pH condition. This leads to frequent false results, leading to improper treatment. The proposed research will advance a novel approach, determining phenotypic PZA susceptibility at neutral pH in a proprietary culture media. This project will optimize the media for PZA susceptibility testing, and the susceptibility testing will be implemented using the standard protocol of TB drug susceptibility testing with reliability and accuracy. Together, this studies will not only establish a reliable PZA susceptibility testing, but also combine all TB drug susceptibilities in one effective system.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.